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LCMVHemorrhagic fevers caused by arenaviruses are among the most devastating emerging human diseases.
Considering the number of individuals affected, the current lack of a licensed vaccine, and the limited
therapeutic options, arenaviruses are arguably among the most neglected tropical pathogens and the
development of efﬁcacious anti-arenaviral drugs is of high priority. Over the past years signiﬁcant efforts have
been undertaken to identify novel potent inhibitors of arenavirus infection. High throughput screening of
small molecule libraries employing pseudotype platforms led to the discovery of several potent and broadly
active inhibitors of arenavirus cell entry that are effective against the major hemorrhagic arenaviruses.
Mechanistic studies revealed that these novel entry inhibitors block arenavirus membrane fusion and
provided novel insights into the unusual mechanism of this process. The success of these approaches
highlights the power of small molecule screens in antiviral drug discovery and establishes arenavirus
membrane fusion as a robust drug target. These broad screenings have been complemented by strategies
targeting cellular factors involved in productive arenavirus infection. Approaches targeting the cellular
protease implicated in maturation of the fusion-active viral envelope glycoprotein identiﬁed the proteolytic
processing of the arenavirus glycoprotein precursor as a novel and promising target for anti-arenaviral
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Arenaviruses are important emerging human pathogens
Several arenaviruses cause severe viral hemorrhagic fevers (VHF) in
humans and represent a serious public health problem (Geisbert and
Jahrling, 2004). Lassa virus (LASV) in Africa causes several hundred
thousand infections per year resulting in signiﬁcant mortality and
morbidity (McCormick and Fisher-Hoch, 2002). On the South American
continent, the arenaviruses Junin (JUNV), Machupo (MACV), Guanarito
(GTOV), and Sabia virus (SABV) have emerged as etiological agents of
severe VHF in Argentina, Venezuela, Bolivia, and Brazil, respectively
164 A.M. Lee et al. / Virology 411 (2011) 163–169(Buchmeier et al., 2007). The worldwide-distributed prototypic arena-
virus lymphocytic choriomeningitis virus (LCMV) is also a neglected
humanpathogenof clinical signiﬁcance, especially in pediatricmedicine
(Barton et al., 2002) and represents a threat to immuno-compromised
individuals, as tragically illustrated by recent fatal cases of transplant-
acquired LCMV infection (Fischer et al., 2006; Palacios et al., 2008). New
arenaviruses emerge on average every three years as illustrated by the
recent discoveries of Chapare virus and Lujo virus that were associated
with fatal hemorrhagic fever cases in Bolivia and Southern Africa,
respectively (Briese et al., 2009; Delgado et al., 2008).
A hallmark of fatal arenavirus VHF is a marked immunosuppres-
sion of the host and consequent uncontrolled fatal infection (Geisbert
and Jahrling, 2004). Those who survive develop a vigorous anti-viral
immune response during the second week of disease, control the
infection, and ultimately clear the virus. Control of acute arenavirus
infection appears to be primarily associated with cellular immunity
rather than neutralizing antibodies (Fisher-Hoch and McCormick,
2004; McCormick and Fisher-Hoch, 2002). Neutralizing antibodies
appear during convalescence and are in case of Lassa fever frequently
of low titer. A highly predictive factor for disease outcome in
arenavirus VHF is the viral load, indicating a close competition
between viral spread and replication and the patient's immune
system (McCormick and Fisher-Hoch, 2002). Anti-viral drugs that
limit viral replication and spread may provide the patient's immune
system a window of opportunity to develop anti-viral immune
responses, to control, and ultimately clear the virus. The development
of novel drugs targeting different steps in the arenavirus life cycle is
therefore a promising strategy to combat arenavirus infection in
humans and will be covered in the present review.
Molecular and cell biology of arenaviruses
Themolecular and cell biology of arenaviruses has been covered by
excellent recent reviews (Buchmeier et al., 2007; de la Torre, 2009)
and only a short summary will be given here. Arenaviruses are
enveloped viruses with a bisegmented negative strand RNA genome
and a life cycle restricted to the cytoplasm. Each genomic RNA
segment L (ca 7.3 kb) and S (ca 3.5 kb) uses an ambisense coding
strategy to direct the synthesis of two polypeptides in opposite
orientation, separated by a non-coding intergenic region (IGR) with a
predicted hairpin structure (Fig. 1). The S RNA encodes the viral
glycoprotein precursor, GPC, and the nucleoprotein, NP, (ca 63 kDa),
whereas the L RNA encodes the viral RNA dependent RNA polymerase
(RdRp, or L polymerase) (ca 200 kDa), and a small RING ﬁnger protein
Z (ca 11 kDa). Arenavirus GPC is synthesized as a single polypeptide
chain (ca 75 kDa) and post-translationally cleaved by the cellular
proprotein convertase (PC) subtilisin kexin isozyme-1 (SKI-1)/site-1
protease (S1P) to yield the mature virion glycoproteins GP1 (40–
46 kDa) and GP2 (35 kDa) (Beyer et al., 2003; Lenz et al., 2001;
Pinschewer et al., 2003; Rojek et al., 2008a). The GP1 part mediates
virus interaction with host cell surface receptors and is located at the
top of the mature GP spike present in the viral envelope. GP1 is
associated via ionic interactions with the transmembrane GP2 that
forms the stalk of the spike. Arenavirus GP2 resembles the fusion-
active membrane-proximal parts of other enveloped viruses. The
cellular receptor for LASV andmost isolates of LCMV isα-dystroglycan
(α-DG), a cell surface receptor for proteins of the extracellular matrix
(ECM) (Cao et al., 1998). The New World arenaviruses JUNV, MACV,
GTOV, and SABV can use human transferrin receptor 1 (TfR1) as a
cellular receptor (Radoshitzky et al., 2007). Upon attachment to the
target cell, arenavirus particles are taken up by endocytosis and
delivered to acidiﬁed endosomes where low pH induces membrane
fusion (Borrow and Oldstone, 1994). New World arenaviruses like
JUNV that use human TfR1 enter the cell via clathrin-mediated
endocytosis (Martinez et al., 2007). In contrast, the Old World
arenaviruses LASV and LCMV, which depend on α-DG, use a distinctand unusual pathway for cell entry that is independent of clathrin,
caveolin, dynamin, and actin and bypasses classical routes of incoming
early endosomal trafﬁcking (Quirin et al., 2008; Rojek et al., 2008b,c).
Formation and release of arenavirus infectious progeny from
infected cells by budding requires that assembled viral RNPs associate
at the cell surface with membranes that are enriched in viral GPs. For
many enveloped RNA viruses viral budding is mediated by a matrix
(M) protein that acts as a bridge between the RNP and GP. In
arenaviruses, the Z protein functions as the main driving force of
arenavirus budding (Perez et al., 2003; Strecker et al., 2003) and the
process is mediated by the Z proline-rich late (L) domainmotifs (PTAP
and PPPY) known to control budding of several other viruses via
interaction with speciﬁc host cell proteins (Freed, 2002).
Current drugs to combat arenaviruses
The only licensed drug for treatment of human arenavirus
infection is the nucleoside analogue ribavirin (Rib) (1-β-D-ribofur-
anosyl-1,2,4-triazole-3-carboxamide) (Parker, 2005). In vitro and in
vivo studies have documented the prophylactic and therapeutic value
of Rib against several arenaviruses. Rib reduced both morbidity and
mortality in humans associatedwith LASV infection (McCormick et al.,
1986), and experimentally in MACV (Kilgore et al., 1995) and JUNV
(Weissenbacher et al., 1987) infections, if given early in the course of
clinical disease. Themechanism of action of Rib against arenaviruses is
currently not entirely clear. Studies in the LCMV model revealed that
the anti-viral effect of Rib is not associated with signiﬁcant increases
in virus mutation frequencies, but has a dramatic effect on viral RNA
synthesis (Ruiz-Jarabo et al., 2003) Over the past two decades efforts
have been made to discover novel drug candidates to combat
arenaviruses and only a short and by no means comprehensive
overview can be given here: inhibitors of IMP dehydrogenase (Andrei
and De Clercq, 1993), the S-adenosylhomocysteine (SAH) hydrolase
(Andrei and De Clercq, 1990), phenotiazines compounds (Candurra
et al., 1996), brassinosteroids (Wachsman et al., 2000) and myristic
acid (Cordo et al., 1999) have been reported to have anti-arenaviral
activity. Several zinc-ﬁnger-reactive compounds with antiretroviral
potential showed activity against arenaviruses (Garcia et al., 2000,
2006) and evidence has been provided for an involvement of the viral
Z protein in their mechanism of action (Garcia et al., 2010). The
pyrazine derivative T-705 (6-ﬂuoro-3-hydrody-2-pyrazinecarboxa-
mide) showed activity against the arenaviruses JUNV, Pichinde
(PICV), and Tacaribe virus (TACV) in vitro and protected against
PICV infection in a hamster model (Gowen et al., 2007), with efﬁcacy
in late stage infection (Gowen et al., 2008).
Early attempts to target arenavirus entry employed sulfated
polysaccharides (Andrei and De Clercq, 1990) and revealed inhibitory
effects of charged polymers on arenavirus infection, however, the
exact mechanism of action remained elusive. A more recent study
evaluated phosphorothioate oligonucleotides in the LCMV model and
revealed that amphipathic DNA polymers are potent inhibitors of
arenavirus infection (Lee et al., 2008). The DNA polymers act at the
level of cell entry and target the interaction between LCMVGP and its
cellular receptor, α-DG, without affecting later steps in replication.
While these studies are of great value as proof-of-principle, to the best
of our knowledge none of these drug candidates has undergone
further evaluation in pre-clinical and clinical trials.
Discovery of novel inhibitors of arenavirus entry by small molecule
screening
Since entry into the host cell is the ﬁrst step of every virus infection it
represents a promising target for attacking the virus before it can gain
control over the host cellmachinery for replication. In recent years, viral
entry inhibitors have emerged as a new class of anti-viral drugs, with
enfuvirtide being successfully used for clinical treatment of humans
Fig. 1. Arenavirus particle and genome organization. (A) Schematic representation of an arenavirus particle. The viral RNA is packaged into ribonucleoparticles (RNP) containing the
viral nucleoprotein (NP). The RNA-dependent RNA polymerase (L) is associated with RNP and required for initial steps of viral transcription. The matrix protein Z associates with the
inner leaﬂet of the viral membrane envelope and interacts with the C-terminal part of the transmembrane GP2 moiety of the mature GP decorating the virion surface. (B) The
ambisense coding strategy of arenaviruses. Each of the two single-stranded RNA segments, L and S, uses an ambisense coding strategy to direct the synthesis of two polypeptides in
opposite orientations and separated by an intergenic region (IGR).
165A.M. Lee et al. / Virology 411 (2011) 163–169infected with human immunodeﬁciency virus (HIV) (Este and Telenti,
2007; Qian et al., 2009) and potent smallmolecule inhibitors for entry of
other viruses, including inﬂuenza (Vanderlinden et al., 2010) and
hepatitis C virus (Baldick et al., 2010) have been reported.
Considering the limited public health infrastructure in endemic
regions, highest priority is given to the development of novel
synthetic drugs against human pathogenic arenaviruses that can be
produced at low cost, delivered orally, and can be stored in tropical
climates. To achieve this goal, several attempts at drug discovery
based on screening large collections of synthetic small molecules have
been undertaken. High throughput screening (HTS) of small molec-
ular libraries has emerged as a major source of potent agonists and
antagonists for a great number of molecular interaction implicated in
a variety biochemical processes (Boger et al., 2003). Despite the
possible involvement of several molecular interfaces, a large number
of studies on protein–protein interaction indicate that in most cases,
small clusters of amino acid residues mediate the energetically most
important interactions (Livnah et al., 1996; Wells, 1996; Wells and de
Vos, 1996; Wrighton et al., 1996) that may be perturbed by small
synthetic molecules. Libraries of small molecules can therefore be
used to screen for and identify molecules that promote protein–
protein interactions (agonists) or inhibit protein–protein interactions
(antagonists) (Boger et al., 1998).
A ﬁrst attempt using HTS of small molecules to identify inhibitors
of arenavirus infection employed a virus-induced cytopathic effect
(CPE)-based assay involving the non-pathogenic New World arena-
virus TACV. HTS of a random library identiﬁed a potent small molecule
inhibitor of TACV and several other New World arenaviruses, ST-294
(Fig. 2) (Bolken et al., 2006), providing proof-of-principle for the
feasibility of this type of approach.
All hemorrhagic arenaviruses are classiﬁed as biosafety level
(BSL)-4 pathogens requiring high security containment laboratories
for work with live viruses. In order to identify speciﬁc inhibitors of cell
entry of hemorrhagic arenaviruses, subsequent drug screening
strategies made use of recombinant retroviruses bearing the GP of
hemorrhagic arenaviruses in their envelope and a luciferase reporter
in their genome (Larson et al., 2008; Lee et al., 2008). Since arenavirus
cell attachment and entry are mediated exclusively by the envelope
GP, these pseudotype platforms allow rapid and reliable screening ofsmall molecule libraries in a HTS format. On one study, pre-selected
combinatorial small molecule libraries were chosen instead of
random libraries, allowing a signiﬁcant reduction of the scope of the
screen to less than 100,000 compounds. Combinatorial chemical
libraries generated by solution-phase synthetic techniques (Boger
et al., 1998) have proven to be powerful sources of novel inhibitors or
agonists of a variety of biochemical interactions. The use of this type of
library has identiﬁed erythropoieitin (EPO) mimetics (promote EPO
receptor dimerization) (Berg et al., 2002), inhibitors of Myc/Max
dimerization (Berg et al., 2002), inhibitors of LEF-1/β-catenin
dimerization (Boger et al., 2000), inhibitors of the binding of the
protease MMP-2 to αvβ3 integrin (Boger et al., 2001; Silletti et al.,
2001), and inhibitors of HIV protease (Chang et al., 2010). Positive
screening of circa 80,000 compounds with LASV pseudotypes yielded
initially circa 1% hits (Lee et al., 2008). Based on the combinatorial
nature of the libraries, the hits tended to appear in clusters of
structurally related compounds. Counter-screening employing pseu-
dotypes of the unrelated vesicular stomatitis virus (VSV) yielded 32
single compounds and 53 mixtures of 4- to 10 compounds each that
speciﬁcally blocked LASV GP-mediated infection. A series of leads
were selected, including the candidate compounds 8C1 and 17C8
(Fig. 2). Candidate compounds 8C1 and 17C8 efﬁciently blocked
infection of cells with live LASV, whereas candidate 17C8, but not 8C1
was also potent against JUNV and other New World hemorrhagic
arenaviruses with comparable IC50 values. Mechanistic studies
revealed that both 8C1 and 17C8 blocked the very last step of viral
entry, pH-dependent membrane fusion. When tested in a cell-based
arenavirus GP fusion assay, these compounds efﬁciently blocked
membrane fusion mediated by the GPs of LASV and JUNV with an IC50
between 200 and 350 nM. The combinatorial nature of the chemical
libraries allowed the identiﬁcation of clusters of structurally related
compounds with differential anti-viral activity, providing the basis for
a ﬁrst assessment of structure–activity-relationship (SAR). Subse-
quent examination of selected compounds in the same series as 17C8
and the related 16G8 (Fig. 2) identiﬁed several additional candidates
that exhibited potent activity against LASV GP-mediated infection
(Whitby et al., 2009). These compounds showed that the benzofuran
and the X-benzyl moieties (X being either methyl- or methoxy-)
impart the activity of the compound against the LASV GP, as
Fig. 2. Arenavirus entry inhibitors identiﬁed in small molecule HTS. (A) Arenavirus entry inhibitors identiﬁed by HTS of a random chemical library (Bolken et al., 2006; Larson et al.,
2008). (B) Inhibitors of arenavirus entry obtained from HTS of combinatorial libraries (Lee et al., 2008). (C) SAR of the candidate compounds 17C8 and 16G8 obtained from the
combinatorial library HTS (Lee et al., 2008). For details please see text.
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different-sized substituents, including methyl, benzyl, and phenethyl
moieties, had no effect on the potency of the compound. Interestingly,
after puriﬁcation of the (R)- and (S)-isomers of 16G8, activity against
the LASV pseudotypes was fully retained with (S)-16G8, whereas (R)-
16G8 showed 15-fold lower activity. This indicates that the stereo-
chemistry of the molecule is important for its function against
arenavirus GP-mediated fusion. A similar effect was also observed
with 17C8, with (S)-17C8 being signiﬁcantly more potent than (R)-
17C8 against LASV pseudotypes (Lee et al., unpublished results). The
requirement for one stereoisomer over another suggests that our
compounds bind to a speciﬁc structure on the GP to exert their effects,
and efforts to identify where the compounds bind the GP and block
fusion are currently underway.
Another screen for LASV entry inhibitors used a chemically diverse
random library of 400,000 small molecule compounds and a lentivirus
pseudotype platform (Larson et al., 2008). Applying a more stringent
cut-off (N75% inhibition at 5 μM), HTS resulted in a hit rate of 1.2%.
However, in contrast to the combinatorial library screen, where
counter-screens reduced the number of hits by less than 50% (Lee
et al., 2008), 90–95% of the hits in the random library screen were
found to be not speciﬁc for LASV pseudotypes and/or cytotoxic
(Larson et al., 2008). The most promising hit, a unique benzimidazolederivative, ST-37 (Fig. 2), exhibited an IC50 of 16 nM against LASV
pseudotypes. Subsequent SAR and lead optimization yielded the
compound ST-193 (Fig. 2) that inhibited pseudotypes of LASV, JUNV,
MACV, GTOV, and SABVwith IC50 of 2–12 nM (Larson et al., 2008). The
candidate ST-193 was also potent against live viruses, supporting the
use of pseudotype platforms for this type of screens. Mechanistic
studies revealed that ST-193 and the formerly identiﬁed New World
arenavirus entry inhibitor ST-294 inhibit GP-mediated membrane
fusion (Larson et al., 2008; York et al., 2008). Interestingly, despite
potent inhibition of cell entry of hemorrhagic arenaviruses by 17C8
and ST-193, both compounds seem to be far less active against LCMV,
whose GP is structurally closely related to LASV (Larson et al., 2008);
Lee et al., unpublished results). The resistance of LCMVGP towards ST-
193 mapped to the C-terminal portion of GP2 and involves two
residues in the transmembrane domain that show divergence
between LCMV on the one hand and the hemorrhagic arenaviruses,
including LASV, on the other hand (Larson et al., 2008). In sum, two
independent small molecule screens using pseudotype platforms in
combination with different library formats identiﬁed a set of broadly
active potent inhibitors of arenavirus fusion. These studies provide
proof-of-principle for this type of approach and establish arenavirus
membrane fusion as a robust drug target to combat a broad range of
arenaviruses. A notable strength of HTS of small molecule libraries is
167A.M. Lee et al. / Virology 411 (2011) 163–169that no information on the structure of the viral envelope protein,
receptor use, andpathwayof endocytosis is needed. This approachholds
therefore a great potential for the rapid discovery of cell entry inhibitors
for newly emerging enveloped viruses that allow pseudotyping.
In addition to serving as promising leads for drug development
against human pathogenic arenaviruses, the prototypic fusion
inhibitors identiﬁed by these recent studies can also be used as
molecular probes to dissect the mechanism of arenavirus membrane
fusion. This is of particular interest in the context of arenaviruses as
studies over the past years revealed unusual and unique features of
arenavirus fusion that are not shared by other enveloped viruses. The
GPs of arenaviruses show overall similarity to fusion-active class I
envelope glycoproteins of other enveloped viruses (Eschli et al.,
2006), but is unusual in that it contains a stable signal peptide (SSP) of
remarkable length that is retained as an essential component of the
fusion-active mature GP complex with the composition SSP/GP1/GP2
(Eichler et al., 2003; York et al., 2004). The arenavirus SSP contains 58
amino acids with two putative transmembrane domains and both the
N- and the C-terminus in the cytosol and plays an important role in
transport, maturation, and fusion-activity of the GP (Agnihothram
et al., 2006, 2007; Saunders et al., 2007; York and Nunberg, 2006; York
and Nunberg, 2007). In particular amino acid substitutions of the
conserved residue K33 in the short ectodomain loop of SSP modulate
the fusion pH of arenavirus GP, indicating an interaction between SSP
and the fusion machinery of GP2. The New World arenavirus entry
inhibitor ST-294 has been used in mechanistic studies to illuminate
molecular details of JUNV fusion (York et al., 2008). Evidence was
provided that ST-294 acts as a fusion inhibitor, targeting the
interaction of the fusion-active GP2 subunit with SSP, and that
amino acid substitutions at the residue K33 of SSP confer resistance to
ST-294. Both ST-294 and the broadly active arenavirus fusion inhibitor
ST-193 inhibit dissociation of GP1 from the SSP/GP1/GP2 complex
induced by low pH, which occur concomitant with conformational
changes in the fusion-active GP2 part (York et al., 2008).
The proteolytic processing of arenavirus glycoprotein precursor as a
novel target for anti-viral therapy
A crucial step in the life cycle of arenaviruses is the proteolytic
processing of the arenavirus GP precursor (GPC) by the cellular protease
SKI-1/S1P, yielding fusion-active, mature GP. Processing of arenavirus
GPC by SKI-1/S1P is essential for productive infection and viral spread
(Beyer et al., 2003;Kunzet al., 2003; Lenz et al., 2001;Rojeket al., 2008a).
In the host cell, SKI-1/S1P is involved in proteolytic processing of a
deﬁned set of cellular proteins, including the sterol regulatory element-
binding proteins (SREBP-1 and SREBP-2), involved in lipid metabolism
(Brown and Goldstein, 1997; Sakai et al., 1998), and the activating
transcription factor 6 (ATF6), involved in the regulation of the cellular
unfolded protein response (Schroder and Kaufman, 2005; Ye et al.,
2000). Interestingly, apart from the arenaviruses, SKI-1/S1P is also
implicated in theproteolytic processingof theenvelopeGPs of thehighly
pathogenic Bunyavirus Crimean Congo HF virus (Vincent et al., 2003).
Efforts to develop speciﬁc inhibitors of SKI-1/S1P resulted in the
design of recombinant serpins able to block SKI-1/S1P activity
(Pullikotil et al., 2004). Expression of SKI-1/S1P-adapted α1-anti-
trypsin variants efﬁciently inhibited the processing of LASV GPC and
had a pronounced impact on production of infectious LASV from
infected cells (Maisa et al., 2009). Another study evaluated a cell-
permeable, peptide-based inhibitor that combines a reactive chlor-
omethylketone (CMK) moiety with peptides derived from the LASV
GPC recognition motif of SKI-1/S1P, decanoyl (dec)-RRLL-CMK
(Pasquato et al., 2006; Rojek et al., 2010). Dec-RRLL-CMK functions
as a fast-acting suicide inhibitor of SKI-1/S1P (Pasquato et al., 2006)
and showed signiﬁcant anti-viral effects against the prototypic LCMV
(Rojek et al., 2010). Off-target effects unrelated to SKI-1/S1P-
mediated GPC processing were excluded employing a recombinantLCMV variant bearing a canonical furin recognition site (RRRR) in its
GPC. Combination of the protease inhibitor with Rib resulted in
additive drug effects. Remarkably, in cells deﬁcient in SKI-1/S1P, the
furin-dependent LCMV variant established persistent infection,
whereas wild-type LCMV underwent extinction without emergence
of SKI-1/S1P-independent escape variants. Together, these studies
strongly suggested that inhibitors of SKI-1/S1P protease represent
promising and powerful anti-arenaviral drug candidates.
The SKI-1/S1P-adapted serpins and the peptide inhibitor dec-
RRLL-CMK used in these proof-of-principle studies both have
limitations in their potential use as an anti-viral in vivo. Recently
small molecule HTS performed by Pﬁzer Inc. identiﬁed a novel SKI-1/
S1P inhibitor, the amino-pyrrolidine amide compound PF-429242
(Hawkins et al., 2008; Hay et al., 2007). PF-429242 blocked SKI-1/S1P-
mediated processing of the transcription factor SREBP in cell culture
and treatment of mice with PF-429242 reduced expression levels of
hepatic SREBP target genes and lowered rates of cholesterol and fatty
acid synthesis (Hawkins et al., 2008). PF-429242 showed high
stability, low toxicity and pharmacokinetic properties that made it
an interesting drug candidate in the context of arenavirus infection.
Indeed, PF-429242 efﬁciently prevented processing of GPC of LCMV
and LASV, which correlated with the compound's potent anti-viral
activity against LCMV and LASV in cultured cells (Urata et al., 2011). In
contrast, a recombinant LCMV expressing a GPC whose processing is
mediated by furin was highly resistant to PF-429242 treatment.
Mechanistically, PF-429242 did not affect virus RNA replication or
budding, and had an only modest effect on virus cell entry, indicating
that the anti-arenaviral activity of PF-429242 wasmostly related to its
ability to inhibit SKI-1/S1P-mediated GPC processing. These ﬁndings
support the feasibility of using the small molecule SKI-1/S1P inhibitor
PF-429242 as a novel anti-arenaviral drug.
Since SKI-1/S1P plays an important role in a number of
physiological processes, including lipid metabolism and ER stress,
the development of inhibitors that speciﬁcally target processing of
arenavirus GPC while having minimal effects on the processing SKI-1/
S1P's cellular substrates has of course highest priority. Nevertheless,
SKI-1/S1P inhibitors like PF-429242 are promising since hemorrhagic
fevers caused by arenaviruses in humans are acute diseases with a
relatively rapid course of infection (Geisbert and Jahrling, 2004;
McCormick and Fisher-Hoch, 2002). Consequently, drug intervention
to treat hemorrhagic arenaviruseswould be restricted to short periods
of time. Dietary supplementation of cholesterol and other lipids to
patients in intensive care appears feasible and would limit unwanted
side-effects of PF-429242 on lipid metabolism. Moreover, cells
deﬁcient in SKI-1/S1P are still able mount a partial ER stress response
(Ye et al., 2000), suggesting that short term inhibition of the SKI-1/S1P
activity may not result in unacceptable levels of toxicity. Therefore,
candidate drugs that lack absolute speciﬁcity and to some degree
affect the processing of cellular targets of SKI-1/S1P may still
represent important candidates to be evaluated as antiviral drugs.
Conclusions and outlook
Considering the signiﬁcance of arenaviruses as important public
health problems, the development of novel and potent anti-arenaviral
drugs that can be manufactured at low costs remains an urgent need.
Small molecule HTS performed over the past years identiﬁed novel
classes of anti-viral drug candidates and provided proof-of-concept
for the feasibility of this strategy for anti-arenaviral drug discovery.
The successful identiﬁcation of potent and speciﬁc inhibitors for
arenavirus cell entry illustrates that small molecule HTS approaches
for anti-viral drug discovery require neither structural information on
the virus, nor knowledge on cellular factors involved. This type of
approach is therefore highly suitable for rapid drug development
against newly emerging human pathogenic viruses, provided their
envelope proteins are amenable for pseudotyping. In addition to viral
168 A.M. Lee et al. / Virology 411 (2011) 163–169entry, virtually every step of the arenavirus replication cycle could be
targeted by this approach. The development of replicon systems for
LASV (Hass et al., 2004), as well as a novel and powerful cell-based
luciferase assay suitable for HTS of inhibitors of arenavirus budding
(Capul and de la Torre, 2008) open the possibility to screen for
compounds that act at additional steps in the viral life cycle. The
availability of inhibitors against distinct steps of viral multiplication
would open the possibility of combinatorial drug use, reducing the
risk of emergence of drug-resistance.
The successful use of newly discovered arenavirus entry inhibitors
to study mechanisms of arenavirus fusion (York et al., 2008)
highlights the potential of small molecule screens to provide novel
small molecule agonists and antagonists that can be used as molecular
probes to dissect biomolecular interactions. In particular the use of
reversible small molecule inhibitors with mid- to low nanomolar
binding afﬁnities and deﬁned drug targets allows the speciﬁc
perturbation of molecular interactions in a dynamic manner due to
micro-reversibility of inhibition. Target-speciﬁc small molecule
compounds identiﬁed in HTS may thus complement other existing
techniques such as genomic knock-out, RNA interference, and
perturbation by antibodies in studies of the molecular interactions
underlying arenavirus infection.
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